克拉斯
癌症研究
鸟苷
医学
激酶
抗体
酪氨酸激酶
突变
化学
鸟苷三磷酸
核苷酸
药理学
小分子
佐剂
伊布替尼
突变体
生物
酪氨酸激酶抑制剂
封锁
抗药性
丝氨酸
鸟嘌呤核苷酸交换因子
肿瘤细胞
作者
Xiangyu Yao,Songfan Wang,Jin Zhong Xie,Fei Chen,Hongxia Qiu,Gang Li,Zhenze Jiang,Weixing Zhang,Xiaoxiao Jiang,Jianguo Chen,Xin Shu,Dan Zhao,Yumeng Li,Yuying Bian,Ke Huang,Litian Jin,Shuai Chen,Zhipeng Yan,Haixia Liu,Wei Zhu
标识
DOI:10.1073/pnas.2621263123
摘要
The clinical durability of first-generation KRAS G12C inhibitors is constrained by resistance mechanisms, primarily the rapid, receptor tyrosine kinase (RTK)-mediated reactivation of KRAS to its drug-insensitive, guanosine triphosphate (GTP)-bound (ON) state. Here, we perform a systematic comparative characterization of clinical and investigational KRAS G12C inhibitors, including Sotorasib, Adagrasib, Divarasib, and Elironrasib, and our structurally optimized tricomplex ON inhibitor, RO7783903 (RO3903). We demonstrate that the covalent tricomplex inhibitors RO3903 and Elironrasib effectively outpace dynamic nucleotide cycling, conferring resilience to potent RTK stimulation and overcoming the secondary KRAS mutations that drive clinical resistance to guanosine diphosphate (GDP)-bound (OFF) state inhibitors. Notably, RO3903 potently inhibits tumor growth in a dose-dependent manner across multiple preclinical models, including an orthotopic intracranial model. Furthermore, RO3903 exhibits synergistic efficacy when combined with inhibitors targeting OFF-state KRAS G12C, YAP-TEAD, EGFR/MET, or FAK, as well as with anti-PD1 antibody and anti-PD1/VEGF bispecific antibody immunotherapies. The high potency, fast target engagement, and brain tumor inhibition of RO3903 position this molecule as a valuable tool reagent and a promising partner for combination strategies to achieve durable tumor regression.
科研通智能强力驱动
Strongly Powered by AbleSci AI